About Zynerba Pharma
Zynerba Pharma is a company based in Devon (United States) founded in 2007 was acquired by Harmony Biosciences in August 2023.. Zynerba Pharma has raised $13 million across 6 funding rounds from investors including Harmony Biosciences, NIH and HHS. The company has 27 employees as of March 31, 2023. Zynerba Pharma offers products and services including Zygel TM. Zynerba Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Devon, United States
- Employees 27 as on 31 Mar, 2023
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Zynerba Pharmaceuticals, Inc.
-
Annual Revenue
$7.25 K-97as on Dec 31, 2016
-
Net Profit
-
EBITDA
-
Total Equity Funding
$13 M (USD)
in 6 rounds
-
Latest Funding Round
-
Investors
Harmony Biosciences
& 5 more
-
Employee Count
27
as on Mar 31, 2023
-
Acquired by
Harmony Biosciences
(Aug 14, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zynerba Pharma
Zynerba Pharma offers a comprehensive portfolio of products and services, including Zygel TM. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Transdermal cannabinoid treatment for neuropsychiatric disorders in rare conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of Zynerba Pharma
Zynerba Pharma has successfully raised a total of $13M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Last Round
-
First Round
First Round
(01 Jun 2007)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2022 | Amount | Post-IPO - Zynerba Pharma | Valuation |
investors |
|
| Oct, 2014 | Amount | Series B - Zynerba Pharma | Valuation | Perceptive Advisors |
|
| Nov, 2009 | Amount | Grant - Zynerba Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Zynerba Pharma
Zynerba Pharma has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Harmony Biosciences, NIH and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward North American opportunities.
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Scientific research on drug use and addiction is supported.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Zynerba Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Zynerba Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Zynerba Pharma Comparisons
Competitors of Zynerba Pharma
Zynerba Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Zynerba Pharma
Frequently Asked Questions about Zynerba Pharma
When was Zynerba Pharma founded?
Zynerba Pharma was founded in 2007.
Where is Zynerba Pharma located?
Zynerba Pharma is headquartered in Devon, United States. It is registered at Devon, Pennsylvania, United States.
Who is the current CEO of Zynerba Pharma?
Jeffrey M Dayno is the current CEO of Zynerba Pharma.
Is Zynerba Pharma a funded company?
Zynerba Pharma is a funded company, having raised a total of $13M across 6 funding rounds to date. The company's 1st funding round was a Grant of $4M, raised on Jun 01, 2007.
How many employees does Zynerba Pharma have?
As of Mar 31, 2023, the latest employee count at Zynerba Pharma is 27.
What is the annual revenue of Zynerba Pharma?
Annual revenue of Zynerba Pharma is $7.25K as on Dec 31, 2016.
What does Zynerba Pharma do?
Zynerba Pharmaceuticals (formerly known as AllTranz) is focused on developing synthetic cannabinoid therapeutics for transdermal delivery. Using its proprietary transdermal technologies, it has developed a controlled delivery of therapeutic levels of two cannabinoids cannabidiol (CBD) and Tetrahydrocannabinol (THC). Its lead candidate ZYN002, a CBD gel, is being studied in refractory epilepsy, FXS, and osteoarthritis. It is also developing ZYN001 which uses pro-drug of THC in a transdermal patch to deliver THC and is currently being studied in fibromyalgia and peripheral neuropathic pain.
Who are the top competitors of Zynerba Pharma?
Zynerba Pharma's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
What products or services does Zynerba Pharma offer?
Zynerba Pharma offers Zygel TM.
Who are Zynerba Pharma's investors?
Zynerba Pharma has 6 investors. Key investors include Harmony Biosciences, NIH, HHS, Perceptive Advisors, and Lincoln Park Capital.